Medincell Rebounds by 4.41% Mid-Day After Four Sessions of Decline
The share price of the French biopharmaceutical company Medincell records a rise of 4.41% this Wednesday, November 12, at mid-day, reaching 31.28 euros, after experiencing a decline of 16.85% over the last seven days. This recovery occurs in a Parisian market itself on the rise, with the CAC 40 gaining 1.14% at 8,248.89 points.
Context of High Volatility for the Montpellier-based Stock
The session is marked by high volatility for the Montpellier-based stock. Over a week, the stock has lost nearly 17% following the disappointing sales forecasts from Teva Pharmaceuticals for sequential sales of Uzedy, the schizophrenia treatment using Medincell's BEPO technology. Trading volumes remain moderate this Wednesday with only 0.15% of the capital traded. Despite this weekly decline, the three-month performance remains spectacular at +98.86%, and the annual increase reaches 70%, significantly outperforming the CAC 40's progression over the same period (+11.07%). In terms of news, Medincell's inclusion in the MSCI World Small Cap index starting November 24, 2025, acts as a positive catalyst that could explain today's technical rebound. This entry reflects the robustness of the company's business model and is expected to enhance its visibility among institutional investors and funds replicating MSCI indices. Additionally, the advancement of Grace Kim to Chief Strategy Officer U.S. Finance, where she acts as a partner in executing the strategy for developing American capital, reflects the group's ambitions in the American market.
Technical Perspective on the Stock
From a technical standpoint, the stock is currently trading above its 50-day moving average (27.63 euros), signaling a favorable short-term momentum. However, the stock is positioned in the median zone of its Bollinger Bands, ranging between 29.77 euros as support and 39.56 euros as resistance, suggesting a lack of a clear directional signal. The RSI at 39 confirms this neutral reading, placing the stock outside of oversold or overbought zones, while the MACD displays a negative histogram at -1.20, indicating a slight slowdown in bullish momentum despite today's rebound. The high volatility of the stock, measured at 18.82% over a month, contrasts with a particularly low beta of 0.29, meaning that Medincell moves relatively independently of the Parisian market. This characteristic, typical of biotech values, is manifested by sharp movements related to the company's specific news rather than the general market trend. The major resistance threshold is at 38.46 euros, while the support is anchored at 24.98 euros, defining a wide corridor that reflects investors' uncertainty about the valuation.
Quarterly Progress Illustrates Growing Market Interest
Over the past quarter, the nearly 99% increase illustrates the growing market interest in the potential of BEPO technology and the commercial prospects of Uzedy. The 200-day moving average at 18.52 euros demonstrates the magnitude of the bullish movement recorded since the beginning of the year, with the price having gained 69% compared to this reference level. The inclusion in the MSCI World Small Cap index, which comprises about 3,840 small capitalizations across 23 developed markets, could generate mechanical investment flows from index funds. However, in the short term, the stock's ability to sustainably exceed the 32 euros threshold will depend on the evolution of Uzedy's quarterly sales, with investors awaiting confirmation of the recovery in the upcoming publications from Teva Pharmaceuticals.
